Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
ABSTRAK Latar belakang: Endometriosis merupakan kelainan ginekologik yang paling sering ditemukan. Seperti halnya endometrium di uterus juga dapat terjadi berbagai perubahan pada epitel yang melapisi kista endometriosis di ovarium, antara lain metaplasia, hiperplasia, atipia bahkan perubahan ke arah keganasan. Saat ini banyak penelitian yang menghubungkan antara endometriosis dan kanker ovarium terutama jenis clear cell dan dikenal dengan istilah endometriosis-associated ovarian carcinoma (EAOC) dan dilaporkan adanya mutasi yang menginaktifkan gen supresor tumor (ARID1A), sehingga protein BAF250a tidak diekpresikan pada Clear cell carcinoma (CCC) ovarii. Bahan dan cara: Dilakukan pulasan imunohistokimia ARID1A pada sampel 20 kasus endometriosis non atipik, 20 kasus atipik dan 20 kasus CCC ovarii tahun 2012 hingga Maret 2015. Dari kelompok kasus CCC didapatkan 9 kasus EAOC. Selanjutnya dilihat adakah perbedaan persentase ekspresi ARID1A pada endometriosis non atipik, atipik, CCC ovarii serta endometriosis disertai CCC (EAOC). Hasil: Pada kelompok kasus endometriosis non atipik, atipik dan CCC ada perbedaan bermakna persentase ekspresi ARID1A (uji Kruskal-Wallis p=0,0035). Selanjutnya dilakukan analisis Post Hoc uji Mann-Whitney dan didapatkan perbedaan bermakna persentase ekspresi ARID1A antara endometriosis non atipik dan atipik dengan CCC ovarii (p=0,001 dan p=0,0015). Pada kelompok kasus endometriosis non atipik, atipik dan endometriosis pada EAOC, didapatkan ada perbedaan bermakna persentase ekspresi ARID1A (Uji Kruskal-Walis p=0,011). Selanjutnya dilakukan analisis Post Hoc uji Mann-Whitney dan ada perbedaan bermakna persentase ekspresi ARID1A antara endometriosis non atipik dan atipik dengan EAOC (p=0,005 dan p=0,008). Kesimpulan: Ekspresi ARID1A pada endometriosis non atipik dan atipik lebih tinggi bermakna dibanding CCC ovarii dan EAOC. Sehingga ekspresi ARID1A kemungkinan dapat digunakan sebagai petanda adanya transformasi ganas pada endometriosis.

---

ABSTRACT Background: Endometriosis is one of the most common gynecological abnormalities found. Endometriosis cyst in the ovary also exhibited changes in epithelial cyst just like endometrium in the uterus. Changes in the epithelial cells also include metaplasia, hyperplasia, atyphia even changes toward malignan characteristics. Nowadays, there are some research that linked endometriosis and clear cell ovarian cancer which is known with endometriosis-associated ovarian carcinoma (EAOC) it is reported that there?s a mutation that activated tumor suppressor gene (ARID1A), so protein BAF250a is not expressed in Clear Cell Carcinoma (CCC) in the ovarium. Materials and Methods: Immunohistochemistry staining of ARID1A were done in 20 samples of non-atypical endometriosis, 20 samples of atypical endometriosis, 20 samples of CCC in the ovarium from the year 2012 until march 2015. From the group that experienced CCC we get 9 cases of EAOC. After that, we see if there?s any difference in the percentage of ARID1A expression in non-atypical endometrosis, atypical endometriosis, CCC in the ovarium and endometriosis with CCC( EAOC). Results: In non-atypical endometriosis, atypical and CCC cases groups there are significant differences on the percentage of ARID1A expression (Kruskal-Walis test p=0,0035). Post Hoc analysis were done using Mann-Whitney test and there are significant differences on ARID1A expression between non-atypical and atypical endometriosis with CCC (p=0,001 and p=0,0015). In non-atypical endometriosis, atypical and EAOC groups there are significant differences on the percentage of ARID1A expression (Kruskal-Walis test p=0,011). Post Hoc analysis were done using Mann-Whitney test and there are significant differences on ARID1A expression between non-atypical and atypical endometriosis with EAOC (p=0,005 and p=0,008). Conclusion: Expression of ARID1A in non atypical and atypical endometriosis are significantly higher compared to ovarian CCC and EAOC. So, we can say that ARID1A may be used as a marker for malignancy transformation in endometriosis.

Abstrak :
Latar belakang: Frekuensi tumor ovarium serosum ganas menempati urutan tertinggi dari seluruh keganasan ovarium di dunia barat 80-85 , sesuai dengan arsip Departemen Patologi Anatomik Fakultas Kedokteran Universitas Indonesia FKUI /Rumah Sakit Cipto Mangunkusumo RSCM selama 10 tahun 2004-2013 , sebanyak 200 kasus 21,4 dari seluruh keganasan ovarium. GLUT-1 dapat digunakan sebagai penanda perangai biologik tumor ovarium serosum. Tujuan penelitian ini membandingkan ekspresi GLUT-1 pada tumor ovarium serosum borderline dan ganas serta faktor risiko.Metode: Penelitian ini menggunakan metode potong lintang. Sampel terdiri atas 17 kasus untuk masing masing kelompok tumor ovarium serosum borderline dan ganas. Dilakukan pulasan GLUT-1 dengan penilaian berdasarkan intensitas dan jumlah sitoplasma dan/atau membran sel yang terpulas. Dilakukan penghitungan histoscore dan persentase setiap kasus dan dinilai ekspresi GLUT-1 berdasarkan titik potong kemudian dikelompokkan menjadi ekspresi rendah dan tinggi.Hasil: Pulasan GLUT-1 ekspresi rendah sama banyak dengan ekspresi tinggi. Sebagian besar kelompok tumor ovarium serosum borderline menunjukkan ekspresi rendah. Kelompok tumor ovarium serosum ganas sebagian besar menunjukkan ekspresi tinggi. Perbedaan ekspresi GLUT-1 antara tumor ovarium serosum borderline dan ganas, secara statistik bermakna p

---

Background The frequency of serous malignant tumors of ovary occupies the highest order of all ovarian malignancies in the western world 80 85 , in accordance with Department of Anatomical Pathology, Faculty of Medicine University of Indonesia Cipto Mangunkusumo hospital datas, for 10 years 2004 2013 , as many as 200 cases 21.4 of all ovarian malignancies. GLUT 1 can be used as a marker in differentiating biological behaviour of serous ovarian tumor. The aim of the study was to compare expression of GLUT 1 in serous borderline and malignant tumours of the ovary. Methods This was cross sectional study. Sample consists of 17 cases for each group, serous borderline and malignant tumor of ovary, stained with GLUT 1 antibody. Quantification was based on the intensity and distribution of cytoplasm and or cell membrane. The appraisal was done with estimating histoscore and percentage of each case. Calculation result was assessed by GLUT 1 expression, based on the point of intersection and then grouped into low and high expression. Result The GLUT 1 low expression results are equal with high expression. Low grade expression found in majority cases of serous borderline ovarian tumors group. Groups of serous malignant ovarian tumors largely exhibit high expression. These differences in Glut 1 expression among the borderline and malignant cases, are statistically significant p